Trelegy Ellipta carries a list price of $697.73 for a 30-day supply, making it one of the more expensive maintenance inhalers on the market. Several factors drive that price: it combines three separate drugs into one device, it’s protected by patents until 2030, the inhaler itself is a complex piece of engineering, and the broader drug pricing system in the U.S. inflates costs at every step.
Three Drugs in One Device
Trelegy isn’t a single medication. It packages three distinct drugs from three different classes: an inhaled corticosteroid that reduces airway inflammation, an anticholinergic that relaxes the muscles around the airways, and a long-acting bronchodilator that keeps airways open for extended periods. Each of these required its own development, clinical testing, and regulatory approval before they could be combined.
Combining all three into a single inhaler also required additional clinical trials to prove the combination was safe, effective, and delivered consistent doses. That layered research and development cost gets built into the price. Before Trelegy existed, patients needing all three drug classes had to use two or even three separate inhalers, which was less convenient but also meant each inhaler competed on price independently.
The Ellipta Inhaler Is Engineered, Not Simple
The delivery device itself is more sophisticated than it looks. The Ellipta inhaler is assembled from 25 separate plastic components and two stainless steel springs. It uses foil-sealed blisters that keep each individual dose protected until the moment you open the mouthpiece cover. That single action simultaneously advances a fresh blister, peels the foil seal, collects the used foil, updates the dose counter, and produces an audible click to confirm activation.
For a triple-therapy inhaler, the device uses a two-strip configuration, meaning it pulls from two separate medication strips in one breath. The airflow geometry inside the inhaler is calibrated to work consistently across a range of breathing strengths, so patients who can only manage a modest inhale still receive a reliable dose. All of this precision manufacturing adds cost that a simple generic pill bottle never would.
No Generic Competition Until at Least 2031
Trelegy’s last qualifying patent doesn’t expire until November 2030. Until then, no generic version can legally enter the U.S. market. At least one generic manufacturer has filed an application with the FDA, but patent protection keeps GSK as the sole supplier for now. Without competition, there’s no market pressure to lower the price.
Generic inhalers are also harder to bring to market than generic pills. A company making a generic tablet just needs to match the active ingredient and show it dissolves the same way. A generic inhaler has to replicate the drug formulation, the particle size, the delivery mechanism, and the device engineering. That’s a higher bar, which means even after patents expire, it can take additional years before a cheaper alternative actually reaches pharmacies.
The Rebate System Inflates List Prices
The sticker price of $697.73 doesn’t reflect what most players in the system actually pay, but it’s the number uninsured patients and many underinsured patients face. Pharmacy benefit managers, the middlemen who negotiate drug prices on behalf of insurers, demand rebates from manufacturers in exchange for placing a drug on preferred formulary lists. Manufacturers respond by raising list prices higher so they can offer larger rebates while still hitting their revenue targets.
This cycle has drawn federal scrutiny. The Federal Trade Commission has taken action against the three largest pharmacy benefit managers for creating what it called a “perverse drug rebate system” that artificially inflates prices. These companies are not required to publicly disclose how much of the rebate they keep versus how much they pass through to insurers or patients. The result is a system where the published price bears little resemblance to the negotiated price, but patients without strong insurance coverage get stuck paying closer to the inflated number.
What Medicare and Insurance Actually Cover
If you have Medicare Part D or a Medicare Advantage plan with drug coverage, Trelegy is typically covered, though it often lands on a higher formulary tier. That generally means coinsurance rather than a flat copay. A common structure is 25% coinsurance, which on a $697 list price would still leave you paying roughly $175 per month before reaching any catastrophic coverage thresholds.
Your actual cost depends heavily on your specific plan, your deductible status, and whether your insurer negotiated a preferred rate. GSK also offers savings programs for commercially insured patients, though eligibility varies. If you’re paying close to list price out of pocket, it’s worth checking both manufacturer assistance programs and your plan’s formulary to see if a preferred alternative exists.
Medicare Price Negotiation Starting in 2027
Trelegy was selected for the second round of Medicare drug price negotiations under the Inflation Reduction Act. The negotiated price will take effect on January 1, 2027, and will apply to Medicare beneficiaries specifically. While the exact negotiated price hasn’t been finalized as of this writing, the first round of negotiations for other drugs produced significant discounts off list prices. For Medicare patients, this could meaningfully reduce out-of-pocket costs within the next couple of years. It won’t directly affect prices for commercially insured or uninsured patients, though it may put indirect pressure on the broader market.